Previous 10 | Next 10 |
2023-05-26 06:38:37 ET Elon Musk's brain-implant company Neuralink said in a tweet that it received approval from the U.S. Food and Drug Administration to conduct human clinical trials of the device. "This is the result of incredible work by the Neuralink team in close collaboration wit...
2023-05-25 19:36:30 ET Summary It is expected that the market opportunity for disease-modifying therapies for MS will reach $29.8 billion in 2030; further projected that OCREVUS could generate sales of $6.3 billion by 2030. Roche Holding AG reported positive results reported from ...
2023-05-22 12:15:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-05-21 12:00:17 ET Developers have increasingly relied on an FDA shortcut to win accelerated drug approvals while their confirmatory trials got delayed at the expense of billions to the government-backed healthcare system, a recent analysis from Bloomberg News indicates. The...
2023-05-19 10:00:52 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips The biotechnology (or biotech) sector is a crystal-clear illustration of risk and reward. Many biotech companies work on drugs and therapeutics for some of the most pernicious conditions affe...
2023-05-19 08:15:00 ET Biogen (NASDAQ: BIIB) and Eli Lilly (NYSE: LLY) both have Alzheimer's drugs that are in development and could obtain approval from the Food and Drug Administration (FDA) within the next 12 months. In trials, both Leqembi (Biogen) and donanemb (Eli Lill...
2023-05-18 11:30:11 ET Cognition Therapeutics ( NASDAQ: CGTX ) stock rose ~9% on Thursday after the company said data for CT1812 was published in the journal Translational Neurodegeneration . The manuscript is titled, 'A Phase 1b Randomized Clinical Trial of CT1812 ...
2023-05-18 11:10:46 ET The U.S. Supreme Court unanimously ruled against Amgen ( NASDAQ: AMGN ) on Thursday in its bid to revive patents related to the PCSK9 cholesterol drug, Repatha, marking a legal victory for partners Sanofi ( NASDAQ: SNY ) and Regeneron ( NASDAQ: REG...
2023-05-17 12:13:55 ET Alzheimer's drug developer Prothena Corporation ( NASDAQ: PRTA ) announced Tuesday that Billy Dunn, who previously led the FDA's Office of Neuroscience, is joining the company's board of directors. The appointment comes less than three months after the FDA...
TOKYO and CAMBRIDGE, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that Health Canada has accepted ...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases ...
TOKYO and CAMBRIDGE, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today tha...
NEW YORK, NY / ACCESSWIRE / June 12, 2024 / Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (Nasdaq:BIIB) Securities Class Action Lawsuit. If you invested in Biogen, you are encouraged to obtain additional information by visiting ...